Generally, point mutations in PLP1 result in X-linked dysmyelinating disorders, such as Pelizaeus-Merzbacher disease (PMD) or spastic paraplegia type 2 (SPG2). Here, PLP1 is linked to Pelizeaus-Merzbacher spectrum disorder.